Medication info
JBKHC Tablet 5/20/12.5 mg

JBKHC Tablet 5/20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Bivozon Pharmaceutical Co., Ltd.
Appearance
White and orange round film-coated tablets
Packaging
30 tablets (10 tablets/Alu-Alu × 3)
Approval status
Active

MFDS item code 201805389 · Approved 2018.12.31 · Insurance code 658204170

Summary

Main use
Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended that you take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation diagram. (The amounts of each component are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. Since experience with this medicine in older adults aged 75 years and older is very limited, they should be monitored very carefully when receiving this medicine.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Bivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with amlodipine and olmesartan combination therapy

  • Essential hypertension
View approved original text

It is important to note that for patients with essential hypertension whose blood pressure is not sufficiently controlled even with combination therapy of Amlodipine and Olmesartan Medoxomil, additional treatment may be necessary. Proper blood pressure control is extremely important for reducing the burden on the heart and blood vessels and lowering the risk of complications. In such cases, the physician may recommend medication adjustment, dose changes, or alternative therapies. It is advisable for patients to engage in lifestyle modifications along with regular blood pressure measurements. Effective blood pressure management helps in the prevention of cardiovascular diseases.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended that you take it at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation diagram. (The amounts of each component are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5mg once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. Since experience with this medicine in older adults aged 75 years and older is very limited, they should be monitored very carefully when receiving this medicine.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies or hypersensitivity to any components of this medication or related drugs should not take it. Pregnant or breastfeeding women, patients with severe hypotension, or those with serious heart or kidney diseases should also not use this medication. Patients with decreased blood volume or electrolyte imbalances may experience hypotension at the initial stages of treatment with this medication, thus careful monitoring is required. Patients with impaired kidney function or those who have received kidney transplants should have frequent blood tests to monitor kidney function and electrolyte status during the use of this medication. Patients with poor liver function or ongoing liver disease may experience serious problems such as hepatic coma, therefore this medication should be administered with caution. This medication lowers blood pressure and may cause dizziness or orthostatic hypotension, so caution is warranted when driving or operating dangerous machinery. The component Hydrochlorothiazide can cause photosensitivity reactions, so the skin should be protected from sun exposure, and if adverse reactions occur, the medication should be discontinued. This medication can affect potassium levels in the blood, so potassium supplements or potassium-sparing diuretics should be used with caution, monitoring blood potassium levels carefully. When used in combination with other antihypertensive agents or certain medications, interactions may increase the risk of side effects, so it is important to consult with a doctor or pharmacist before use. Elderly patients might have decreased kidney and liver function, so it is advised to start at a low dose and adjust carefully. In the case of overdose, severe hypotension, palpitations, electrolyte imbalances may occur, and immediate medical attention is required for proper treatment. The safety and efficacy of this medication have not been established in children, so its use is not recommended. Store this medication in a place out of reach of children and avoid humidity, heat, and direct sunlight.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylaxis, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity, anxiety, mood changes, sleep disturbances, neurological abnormalities, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, syncope, seizures, loss of appetite, tremor, visual disturbances, reduced tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, sweating, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, muscle paralysis, myalgia, bone pain, polyuria, acute kidney failure, hematuria, urination disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, weakness, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated blood creatinine, elevated blood urea, elevated blood uric acid, decreased blood potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated creatine phosphokinase in the blood, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, drug hypersensitivity, epigastric pain, decreased libido, labial edema, lethargy, altered consciousness, eczema, limb pain, mild decreases in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is recommended to keep the storage temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness and safety of the drug over time.

Appearance and packaging

Appearance

White and orange round film-coated tablets

Package unit

30 tablets (10 tablets/Alu-Alu × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.